Running trials whose results could change what is known, in three areas where people with MS most want progress. They are chosen every week by the same rules: randomised, phase 2 or later, at least 40 participants, no result yet, and higher in the list when they are larger, further along, due to report sooner, or testing an approach not yet confirmed for that group of people.
Phase 3 · 943 participants · frexalimab · results due March 2028
New for this groupPhase 3 · 943 participants · tests frexalimab · in relapsing and progressive MS. Not yet confirmed for this group: T-cell co-stimulation / cytokine targeting. Main results due March 2028.
Phase 3 · 204 participants · cladribine · results due December 2027
New for this groupPhase 3 · 204 participants · tests cladribine · in progressive MS. Not yet confirmed for this group: Immune reconstitution (cladribine, alemtuzumab, aHSCT). Main results due December 2027.
Phase 3 · 188 participants · cladribine · results due June 2027
New for this groupPhase 3 · 188 participants · tests cladribine · in relapsing and progressive MS. Not yet confirmed for this group: Immune reconstitution (cladribine, alemtuzumab, aHSCT). Main results due June 2027.
Phase 3 · 1,200 participants · metformin, thioctic acid · No date given
New for this groupPhase 3 · 1,200 participants · tests metformin, thioctic acid · in progressive MS. Not yet confirmed for this group: Mitochondrial / oxidative stress.
Phase 3 · 990 participants · orelabrutinib · results due June 2030
Phase 3 · 990 participants · tests orelabrutinib · in relapsing and progressive MS. Main results due June 2030.
Phase 3 · 705 participants · orelabrutinib · results due June 2030
Phase 3 · 705 participants · tests orelabrutinib · in progressive MS. Main results due June 2030.
Phase 3 · 1,275 participants · remibrutinib · results due December 2030
Phase 3 · 1,275 participants · tests remibrutinib · in progressive MS. Main results due December 2030.
Phase 2 · 360 participants · ocrelizumab · results due May 2028
New for this groupPhase 2 · 360 participants · tests ocrelizumab · in progressive MS. Not yet confirmed for this group: B-cell depletion (anti-CD20). Main results due May 2028.
Phase 3 · 1,200 participants · metformin, thioctic acid · No date given
New for this groupPhase 3 · 1,200 participants · tests metformin, thioctic acid · in progressive MS. Not yet confirmed for this group: Mitochondrial / oxidative stress.
Phase 3 · 220 participants · fish oil · No date given
New for this groupPhase 3 · 220 participants · tests fish oil · in relapsing MS. Not yet confirmed for this group: Vitamin D and nutritional supplements.
Phase 3 · 60 participants · levetiracetam · No date given
New for this groupPhase 3 · 60 participants · tests levetiracetam · in MS. Not yet confirmed for this group: Axonal protection / ion channels / excitotoxicity.
Phase 2 · 120 participants · metformin · results due February 2027
New for this groupPhase 2 · 120 participants · tests metformin · in progressive MS. Not yet confirmed for this group: Mitochondrial / oxidative stress. Main results due February 2027.
Phase 2 · 98 participants · acetylcysteine · results due February 2027
New for this groupPhase 2 · 98 participants · tests acetylcysteine · in progressive MS. Not yet confirmed for this group: Mitochondrial / oxidative stress. Main results due February 2027.
Phase 2 · 90 participants · clemastine · results due August 2028
New for this groupPhase 2 · 90 participants · tests clemastine · in MS. Not yet confirmed for this group: Remyelination / oligodendrocyte repair. Main results due August 2028.
Phase 2 · 60 participants · ifenprodil · results due March 2027
New for this groupPhase 2 · 60 participants · tests ifenprodil · in relapsing MS. Not yet confirmed for this group: a new approach. Main results due March 2027.
Phase 2 · 40 participants · natalizumab · results due October 2027
New for this groupPhase 2 · 40 participants · tests natalizumab · in early MS (CIS or RIS). Not yet confirmed for this group: Integrin blockade (lymphocyte trafficking). Main results due October 2027.
Phase 3 · 204 participants · cladribine · results due December 2027
New for this groupPhase 3 · 204 participants · tests cladribine · in progressive MS. Not yet confirmed for this group: Immune reconstitution (cladribine, alemtuzumab, aHSCT). Main results due December 2027.
Phase 3 · 188 participants · cladribine · results due June 2027
New for this groupPhase 3 · 188 participants · tests cladribine · in relapsing and progressive MS. Not yet confirmed for this group: Immune reconstitution (cladribine, alemtuzumab, aHSCT). Main results due June 2027.
Phase 3 · 156 participants · Immune reconstitution (cladribine, alemtuzumab, aHSCT) · results due August 2030
New for this groupPhase 3 · 156 participants · in relapsing and progressive MS. Not yet confirmed for this group: Immune reconstitution (cladribine, alemtuzumab, aHSCT). Main results due August 2030.
Phase 2 · 120 participants · CAR-T cell therapy · results due April 2027
New for this groupPhase 2 · 120 participants · in progressive MS. Not yet confirmed for this group: CAR-T cell therapy. Main results due April 2027.
Phase 2 · 45 participants · Cell therapies and tolerisation · results due October 2027
New for this groupPhase 2 · 45 participants · in progressive MS. Not yet confirmed for this group: Cell therapies and tolerisation. Main results due October 2027.
Phase 2 · 350 participants · plovamer acetate · No date given
New for this groupPhase 2 · 350 participants · tests plovamer acetate · in relapsing MS. Not yet confirmed for this group: Cell therapies and tolerisation.
Phase 2 · 61 participants · tenofovir alafenamide · No date given
New for this groupPhase 2 · 61 participants · tests tenofovir alafenamide · in MS. Not yet confirmed for this group: Antiviral / EBV-targeting.
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error